

March 13, 2002



Document Processing Center (7407)
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
401 M Street SW
Washington, D.C. 20460

Attention: **For Your Information Docket – Docket No. AR-226**

Re: Information on Perfluorooctane
Sulfonates and Related Compounds

Dear Sir or Madam:

This continues 3M's voluntary submissions of data on perfluorooctane sulfonates and related compounds, as part of our ongoing dialogue with EPA regarding fluorochemicals.

Enclosed you will find the following:

1. Final Report, Identification of Fluorochemicals in Human Sera. I. American Red Cross Adult Blood Donors, February 25, 2002.
2. Final Report, Identification of Fluorochemicals in Human Sera. II. Elderly Participants of the Adult Changes in Thought Study, Seattle, Washington, February 25, 2002.
3. Final Report, Identification of Fluorochemicals in Human Sera. III. Pediatric Participants in a Group A Streptococci Clinical Trial Investigation, February 25, 2002.
4. Interim Report #2, Determination of Serum Half-Lives of Several Fluorochemicals, January 11, 2002.
5. Final Report, A Longitudinal Analysis of Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) in Relation to Clinical Chemistry, Thyroid Hormone, Hematology and Urinalysis Results from Male and Female Employee Participants of the 2000 Antwerp and Decatur Fluorochemical Medical Surveillance Program, October 11, 2001. This report was previously submitted on December 20, 2001. The report submitted today includes some corrections from the previous version.


6. Final Report, A Longitudinal Analysis of Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) Levels in Relation to Lipid and Hepatic Clinical Chemistry Test Results from Male Employee Participants of the 1994/95, 1997 and 2000 Fluorochemical Medical Surveillance Program, October 11, 2001. This report was previously submitted on December 20, 2001. The report submitted today includes some corrections from the previous version.

In addition, 3M contracted with Dr. David Gaylor of Sciences International, Inc. to calculate benchmark doses for low-dose cancer risk assessment based on the results from the cancer bioassays in rats with N-EtFOSE and PFOS. These two-year bioassay reports were submitted on January 30, 2002. Dr. Gaylor's reports provide values for the lower 95th percent confidence limit of the benchmark dose (BMDL₁₀) in terms of dietary concentration of N-EtFOSE or PFOS, respective to the test compound used in the study, and serum PFOS concentration, as measured at 14-weeks of dosing.

7. Benchmark Doses for Tumor in Sprague Dawley Rats fed N-Ethyl Perfluorooctanesulfonamido Ethanol (N-EtFOSE), January 31, 2002.
8. Benchmark Doses for Liver Tumors in Sprague Dawley Rats fed Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), January 24, 2002.

We will continue to provide information as it becomes available. Please feel free to contact me with any questions.

Very truly yours,



Michael A. Santoro
Director of Environmental, Health
Safety and Regulatory Affairs
Specialty Materials Markets
3M Center, Building 236-1B-10
St. Paul, MN 55144
651-733-6374 (phone)
651-733-1958 (fax)
E-mail: masantoro@mmm.com

cc: Dr. Charles Auer
Dr. Oscar Hernandez